Skip to content

The novel μ-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)2653-2661
Number of pages9
JournalBritish Journal of Pharmacology
Volume175
Issue number13
Early online date14 May 2018
DOIs
DateAccepted/In press - 17 Mar 2018
DateE-pub ahead of print - 14 May 2018
DatePublished (current) - 15 Jul 2018

Abstract

Background and Purpose: PZM21 is a novel μ-opioid receptor ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ receptor ligands such as morphine. We have re-examined the signalling profile of PZM21 and its ability to depress respiration.

Experimental Approach: G protein (Gi) activation and arrestin-3 translocation were measured in vitro, using BRET assays, in HEK 293 cells expressing μ receptors. Respiration (rate and tidal volume) was measured in awake, freely moving mice by whole-body plethysmography, and antinociception was measured by the hot plate test.

Key Results: PZM21 (10−9 – 3 × 10−5 M) produced concentration-dependent Gi activation and arrestin-3 translocation. Comparison with responses evoked by morphine and DAMGO revealed that PZM21 was a low efficacy agonist in both signalling assays. PZM21 (10–80 mg·kg−1) depressed respiration in a dose-dependent manner. The respiratory depression was due to a decrease in the rate of breathing not a decrease in tidal volume. On repeated daily administration of PZM21 (twice daily doses of 40 mg·kg−1), complete tolerance developed to the antinociceptive effect of PZM21 over 3 days but no tolerance developed to its respiratory depressant effect.

Conclusion and Implications: These data demonstrate that PZM21 is a low efficacy μ receptor agonist for both G protein and arrestin signalling. Contrary to a previous report, PZM21 depresses respiration in a manner similar to morphine, the classical opioid receptor agonist.

    Research areas

  • Journal Article

Download statistics

No data available

Documents

Documents

  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via Bristish Journal of Pharmacology at https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bph.14224. Please refer to any applicable terms of use of the publisher.

    Final published version, 635 KB, PDF document

    Licence: CC BY

DOI

View research connections

Related faculties, schools or groups